{
  "id": 6648305,
  "title": "Jim Cramer Calls Natera (NTRA) “a Promising Story”",
  "url": "https://urgent.news/2026/09/09/jim-cramer-calls-natera-ntra-a-promising-story",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-09T13:33:39.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-calls-natera-ntra-133339649.html"
  },
  "original_language": "en",
  "account": "Jim Cramer praised Natera (NTRA) as a \"promising story\" on his September 3 episode of Mad Money. He described the company as a \"precision medicine platform\" that is expanding into oncology, women's health, and organ transplantation. Natera reported a 37.7% year-over-year revenue increase to $752.8 million, with oncology test volumes up 57.2% and gross margin reaching 64.5%. The company's personalized blood-based cancer test, Signatera, is a key growth driver, with clinical molecular residual disease volume increasing 56% year-over-year.\n\nCramer noted that analysts estimate the solid-tumor MRD market could eventually be worth $20 billion-$30 billion, but stressed that Natera currently holds only a small portion of this market. The company has expanded its transplant business, with Medicare surveillance coverage for Prospera taking effect on August 30 across kidney, heart, and lung transplant recipients. Natera also received regulatory approval in Japan for colorectal cancer.\n\nDespite the company's expansion, Cramer warned that Natera's valuation has become difficult to justify, trading at roughly 16 times its expected sales rather than earnings. The company remains unprofitable, reporting a $67 million net loss in the second quarter, and is projected to face substantial research and development expenses of $800 million-$900 million. Cramer highlighted risks such as competition, reimbursement, regulatory requirements, clinical validation, and adoption of its tests.\n\nDespite these challenges, Cramer advised investors to wait for a pullback before buying Natera, emphasizing that the company is not cheap or undiscovered. Insider Monkey reports that 77 hedge funds held NTRA as of June 30, up from 68 in the first quarter, and short interest remains relatively low at about 3.1% to 3.2% of the float.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}